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ISSNObjective: We assessed the relationship between phasing out stavudine in first-line
antiretroviral therapy (ART) in accordance with WHO 2010 policy and single-drug
substitutions (SDS) (substituting the nucleoside reverse transcriptase inhibitor in first-
line ART) in sub-Saharan Africa.
Design: Prospective cohort analysis (International epidemiological Databases to Evalu-
ate AIDS-Multiregional) including ART-naive, HIV-infected patients aged at least 16
years, initiating ART between January 2005 and December 2012. Before April 2010
(July 2007 in Zambia) national guidelines called for patients to initiate stavudine-based
or zidovudine-based regimen, whereas thereafter tenofovir or zidovudine replaced
stavudine in first-line ART.
Methods: We evaluated the frequency of stavudine use and SDS by calendar year
2004–2014. Competing risk regression was used to assess the association between
nucleoside reverse transcriptase inhibitor use and SDS in the first 24 months on ART.
Results: In all, 33 441 (8.9%; 95% confience interval 8.7–8.9%) SDS occurred among
377656 patients in the first 24 months on ART, close to 40% of which were amongst
patients on stavudine. The decrease in SDS corresponded with the phasing out of
stavudine. Competing risks regression models showed that patients on tenofovir were
20–95% less likely to require a SDS than patients on stavudine, whereas patients on
zidovudine had a 75–85% decrease in the hazards of SDS when compared to
stavudine. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
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 148 AIDS 2017, Vol 31 No 1Conclusion: The decline in SDS in the first 24 months on treatment appears to be
associated with phasing out stavudine for zidovudine or tenofovir in first-line ART in our
study. Further efforts to decrease the cost of tenofovir and zidovudine for use in this
setting is warranted to substitute all patients still receiving stavudine.
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In sub-Saharan Africa, an estimated 11.4 million HIV-
positive individuals were receiving antiretroviral therapy
(ART) by mid-2015 [1]. In low and middle-income
countries (LMICs), HIV treatment programs take a public
health approach that utilizes 12 antiretrovirals in four drug
classes [2,3]. Since treatment options are limited in
LMICs and at least three drugs from two drug classes are
typically needed for effectiveness, therapeutic options
need to be maximized. One way to increase the life span
of first-line ART in patients in LMICs is by decreasing
rates of substituting individual drugs, typically for reasons
of toxicity, within the regimen [single-drug substitutions
(SDS)].
Prior to the WHO guidelines change in 2010, the most
frequently used nucleoside reverse transcriptase inhibitor
(NRTI) alongside lamivudine was stavudine [2,3].
Stavudine is highly effective in treating HIV [4], but is
associated with severe side effects [5–7]. In 2009, as a
result of stavudine’s poor side-effect profile, the WHO
recommended replacing stavudine with tenofovir or
zidovudine for initial HIV treatment [4]. In 2010, most
governments in LMICs followed suit and began to phase
out stavudine and replace it with tenofovir or zidovudine,
for all new ART initiates [8]. Since there are fewer side
effects and drug toxicities associated with tenofovir and
zidovudine than stavudine [4,9–11], the switch was
expected to be accompanied by a marked decrease in SDS
in first-line ART.
To date, several observational studies set in LMICs have
compared rates of SDS amongst patients on stavudine,
tenofovir, and zidovudine-based regimens. All studies
found that patients on tenofovir had about an 82%
decrease in the risk of SDS [summary risk ratio 0.18, 95%
confidence interval (CI) 0.15–0.20] compared to patients
on stavudine [12–20], whereas patients on zidovudine,
although at higher risk of SDS compared to tenofovir,
remained at lower risk of substitution compared to
patients on stavudine (summary risk ratio 0.41, 95% CI
0.37–0.45) [12–17].
Whereas previous observational studies do suggest
tenofovir and zidovudine are associated with fewerCopyright © 2016 Wolters Kluwer HSDS compared to stavudine [12–20], many had
important limitations. Two studies [12,13] included
patient populations that initiated tenofovir prior to
implementation of the 2010 WHO policy change. These
patients would be more likely to have initiated tenofovir
because of contraindications to stavudine or zidovudine,
leading to strong confounding by indication. We sought
to use one of the largest HIV database in the world to
assess whether or not the phasing out of stavudine in first-
line ART in accordance with WHO 2010 policy
decreased SDS in sub-Saharan Africa. This transition
allows evaluation of the impact of a major policy change
while accounting for secular trends in improvements in
HIV treatment.Methods
Cohort description
The International epidemiological Databases to Evaluate
AIDS (IeDEA, www.iedea.org) is a worldwide National
Institute of Health sponsored collaboration of HIV
treatment cohorts. This study included cohorts from
Southern Africa, East Africa, and West Africa [21]. Data
are collected on patients at the start of ART and at each
follow-up visit. Clinic information includes demo-
graphic, clinical, and HIV regimen data. Before April
2010 (2007 in Zambia), if a patient experienced side
effects or toxicities related to stavudine or zidovudine, and
was not in need of second-line therapy, the recommen-
dation was to substitute stavudine with either zidovudine,
if no related anemia or neutropenia was present, or
abacavir, and to substitute zidovudine with either
stavudine or abacavir [22–28]. After April 2010 (2007
in Zambia), patients initiated onto stavudine or
zidovudine now had tenofovir if no signs of renal
insufficiency were detected, whereas those initiated onto
tenofovir could substitute with stavudine, zidovudine, or
abacavir [22–28].
All IeDEA sites obtained ethical approval from relevant
local institutions before contributing anonymized patient
data. Approval for analysis of de-identified data was
granted by Boston University’s Institutional Review
Board.ealth, Inc. All rights reserved.
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We performed a cohort analysis of data collected
prospectively as part of routine care at clinics in the
IeDEA multiregional collaboration. We included ART-
naı¨ve, HIV-infected patients aged at least 16 years
initiating first-line ART between 1 January 2005 and
31 December 2012, for all countries except Nigeria,
where patients initiating ART between 1 January 2007
and 31 December 2012 were included as the roll out of
ART started later. All patients had the potential for
24 months of follow-up. Prior to April 2010, national
HIV treatment guidelines recommended the use of
stavudine or zidovudine in first-line ART in all six
included countries; thereafter, guidelines called for
tenofovir or zidovudine to replace stavudine [22–26].
The only exception was in Zambia, which switched from
stavudine or zidovudine to tenofovir in July 2007 [27,28].
Study variables
All demographic (i.e. age, sex, clinic, and country) and
clinical [i.e. year of ART initiation, CD4þ cell count,
hemoglobin levels, weight, WHO stage, first-line NRTI
(stavudine, zidovudine, or tenofovir), and non-nucleo-
side reverse transcriptase inhibitor (NNRTI) (nevirapine
or efavirenz)] characteristics measured at ART initiation
came from routinely collected clinic data. WHO staging
was not available for East African countries.
The primary outcome variable was the proportion of
patients who underwent a SDS in the first 24 months of
ART. Follow-up time of 24 months was chosen as
monitoring and time to development of toxicity/side
effects differ between drugs. Laboratory monitoring for
tenofovir and zidovudine is conducted early on after
treatment initiation, whereas for stavudine, monitoring
begins more often when the patient begins to develop
clinical symptoms of toxicity (up to 24–48 months on
ART [29]) diagnosed at a medical visit [2,3]. SDS was
defined as substitution of the NRTI only within first-line
ART. The reason for SDS was not available.
Statistical analysis
Patient characteristics at ART initiation were summarized
with descriptive statistics and stratified by country. To
look for trends in the use of stavudine in first-line ART
and SDS over time, proportions of patients initiating
stavudine or having a SDS in the first 24 months on ART
were stratified by country and year of ART initiation, and
plotted from 1 January 2005 to 31 December 2012,
separately, with Nigeria being the exception, as data
collection began in 2007. To test an additional hypothesis
that tenofovir was being used among patients with
contraindications to stavudine prior to guideline change,
we looked at rates of SDS by NRTI over time.
Fine and Gray’s [30] competing risks regression method
was used to identify if the choice of NRTI in first-line
ART was a predictor of SDS in the first 24 months on Copyright © 2016 Wolters KluweART, accounting for attrition as competing risks, and
adjusted for age, sex, year of ART initiation, CD4þ cell
count, hemoglobin levels, WHO stage, and first-line
NNRTI depending on country, with robust estimates at
site level. We ran two models for each country. In both,
we included all demographic and clinical characteristics
at treatment initiation and year of ART initiation. The
models differed as year of treatment initiation and NRTIs
used were highly associated, and therefore each model
used only one of the two. Follow-up time began at
ART initiation and ended at the earliest of SDS; initiation
of second-line ART; discontinuation of treatment; loss
to follow-up (defined as not attending the clinic in the
last 6 months); death; transfer; completion of 24-months
of follow-up; or date of dataset closure (31 December
2014).
We assessed interaction between sex and NRTI, CD4þ
cell count and NRTI, hemoglobin levels and NRTI,
CD4þ cell count and sex, WHO stage and sex, and
hemoglobin levels and sex on the additive scale by
calculating the risk due to interdependence [R(I)] [31].
Bayesian analysis
As this is not the first study on the topic and we can draw
stronger conclusions when incorporating those prior
results into our current analysis, we conducted a Bayesian
analysis which allows incorporation of the result of prior
knowledge about the relationship between the exposure
and the outcome into the estimation of parameters. Our
approach to Bayesian analysis [32] is essentially a weighted
average incorporating the prior distribution (previous
literature) and our data. To do this, point estimates and
corresponding 95% CIs for priors were obtained from
previous publications assessing predictors of SDS
[12–20]. Ratio measures for each potential predictor of
SDS (age, sex, clinic, CD4þ cell count, weight,
hemoglobin levels, WHO stage, NRTI, and NNRTI
used in first-line regimen)were extracted from the existing
literature. We performed a meta-analysis using random-
effects models, due to heterogeneity in estimates, to first
create weighted summary estimates for each individual
predictor, separately, from the existing literature (referred
to as the ‘prior’). The same technique was used to calculate
the summary estimates of each individual predictor,
separately, from our data (referred to as the ‘likelihood’)
and then combined the prior and likelihood estimates for
each predictor, separately, to calculate a combined
summary estimate (referred to as the ‘posterior’) and
corresponding Bayesian credible intervals (CrIs).
Sensitivity analysis
As we may have had unmeasured confounding in our
population, we conducted a multidimensional sensitivity
analysis [33] by making assumptions about the strength of
the effect of an unmeasured confounder on SDS and its
prevalence in both patients on tenofovir or zidovudine
(exposed) and those on stavudine (unexposed). We werer Health, Inc. All rights reserved.
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the effect of exposure to tenofovir or zidovudine. We
considered a confounder that would increase SDS and
was more prevalent in patients on stavudine. We then
back-calculated the relative risk we would have observed
had we collected data on and adjusted for the purported
confounder [33].
Multiple imputation
To account for missing data, we used multiple imputation
by chained equations method using PROC MI in SAS
[34] and assumed that the data were missing at random
[35]. All models were fitted using 25 imputed datasets and
estimated coefficients combined by averaging with the
MIANALYZE procedure in SAS [36]. All clinical and
demographic variables were included in the imputed
models in addition to the outcome of SDS and indicator
variables for death and loss to inform the missingness, but
were not imputed. Appropriate standard errors were
calculated using the within and between imputation
standard errors of the estimates using Rubin’s rules [35].
Since models based on imputed results did not differ from
the models on the original data we displayed the results
based on the original data.Results
We included 377 656 patients in the analysis (Table 1) –
24% initiated a stavudine-based ART regimen, ranging
from 25% in Zambia andUganda, to 60% in South Africa.
Zambia contributed the largest number of patients
(n¼ 205 140) and Nigeria the smallest (n¼ 7434).
Demographic and clinical characteristics were similar
across countries. Patients were predominately female
(62.9%) with a median age of 35.2 years [interquartile
range (IQR) 29.8–42.0] and a median time on treatment
of 24.0 months (IQR 12.1–24.0), which did not differ by
cohort. At ART initiation, patients had a median CD4þ
cell count of 155 cells/ml (IQR 74–241), with patients in
South Africa having the lowest median (130 cells/ml,
IQR 58–199) andNigeria the highest (192 cells/ml, IQR
91–312).
When stratified by year, sex, weight, and age remained
unchanged over time, whereas patients’ cellular immu-
nity at ART initiation improved in all countries.
Additionally, the proportion of patients with tuberculosis
and WHO III/IV stage declined over time in South
Africa. Over 70% of patients in all countries remained
alive and in care over 24 months on treatment. Overall
attrition (combination of death and loss to follow-up)
was 17.8% (95% CI 17.7–17.9%) and fairly consistent
across countries, with Zambia having the lowest rate of
attrition in the first 24 months on ARTat 15.3% (95% CI
15.2–15.5%) and Nigeria the highest at 23.5% (95% CI
22.5–24.4%). Copyright © 2016 Wolters Kluwer HCompliance with WHO guidelines: phasing out
of stavudine in first-line antiretroviral therapy
All countries, with the exception of South Africa, where,
in 2009, 95% of patients still initiated stavudine, began
phasing out stavudine prior to the WHO guidelines,
making the change in 2010 (Fig. 1). Zambia, Kenya, and
Uganda began replacing stavudine with zidovudine in
first-line ART as early as 2007 (2005 in Zambia),
potentially in parallel with the WHO’s recommendation
for lower-dose stavudine use (30mg instead of 40mg
[37]). Tenofovir was introduced after the WHO
recommended its use in first-line therapy in 2010
(2007 in Zambia); as such, within 2 years of the change
in 2012, fewer than 10% of patients were being initiated
on stavudine. Prior to 2010, in Cote d’Ivoire andNigeria,
stavudine and zidovudine were used interchangeably,
whereas stavudine use decreased substantially, with less
than 10% of patients initiating the drug after 2010, when
both countries decided on zidovudine as the NRTI of
choice in first-line ART. Tenofovir was yet to be
introduced in first-line ART in Cote d’Ivoire or Nigeria
before 2012 due to cost [3].
Decrease in single-drug substitutions associated
with the phase out of stavudine
Whereas the WHO policy change was accompanied by a
clear shift away from stavudine to tenofovir, the impact on
single-drug substitutions is less clear. Overall, SDS
affected 8.8% (95% CI 8.7–8.9%) of patients in the first
24 months on ART, with 38% of SDS related to stavudine
compared to 49 and 13% related to zidovudine and
tenofovir, respectively. The decrease in SDS was
associated with the phasing out of stavudine in first-
line ART, decreasing from an overall rate of 11.3% (95%
CI 11.2–11.4%) prior to 2010, when 55% of patients
were initiating stavudine, to 5.4% (95% CI 5.3–5.5%)
after 2010, when only 7.4% of patients initiated treatment
with this drug. However, it is important to note that in all
countries, SDS began roughly 2 years prior to the WHO
guideline change in 2010 (Fig. 2). For all countries,
competing risks regression models adjusted for year
confirmed our results, showing a decrease in the hazards
of SDS in accordance with the decrease in the use of
stavudine (Supplementary Table 1, http://links.lww.
com/QAD/A998).
Single-drug substitutions stratified by initiating
nucleoside reverse transcriptase inhibitor and
substitution nucleoside reverse transcriptase
inhibitor
In addition to the variation observed in relation to the
policy change, we also observed differences in rates of
substitution by treatment regimen. Patients initiating
stavudine (13.9%; 95% CI 13.7–14.1%) and zidovudine
(12.0%; 95% CI 11.8–12.2%) had higher rates of single-
drug substitution compared to patients initiating teno-
fovir (2.8%; 95% CI 2.7–2.9%). Also, whereas rates of
substitution decreased over time for patients on tenofovir,ealth, Inc. All rights reserved.
 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
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Fig. 1. Trends in the stavudine use in first-line ART for treatment-naive patients stratified by country and year since ART
guidelines changed (NU377656).Dashed lines represent the change in national guidelines to introduce zidovudine or tenofovir
into first-line ART (2007 for Zambia and 2010 for all other countries). ART, antiretroviral therapy.they remained stable for zidovudine patients and
increased for those on stavudine (Supplementary
Fig. 1, http://links.lww.com/QAD/A998). All countries
followed the national ART guidelines outlining the
antiretrovirals eligible for substitution. These included
tenofovir, stavudine, zidovudine, or abacavir depending Copyright © 2016 Wolters Kluwer H
Fig. 2. Proportion of single-drug substitutions over the first 24 mo
for all countries (NU377656). Dashed lines represents the chang
into first-line ART (2007 for Zambia and 2010 for all other countron NRTIs included in the first-line regimen with the
occasional use of didanosine as an alternative(Supple-
mentary Fig. 2, http://links.lww.com/QAD/A998).
Zidovudine was the most common SDS used for both
tenofovir (50%; 95% CI 48.6–51.6%) and stavudine
(67.9%; 95% CI 67.2–68.6%), whereas stavudine was theealth, Inc. All rights reserved.
nths on ART stratified by year since ART guidelines changed
e in national guidelines to introduce zidovudine or tenofovir
ies). ART, antiretroviral therapy.
Decrease in toxicity with phasing out stavudine Brennan et al. 153SDS for a zidovudine-based first-line regimen (65.1%;
95% CI 64.2–66.0%).
Consistent with known toxicity patterns, SDS occurred
earlier for patients on zidovudine (median 8.1 months
after start of treatment; IQR 2.3–17.0) and tenofovir
(median 10.2 months after start of treatment; IQR 3.6–
18.1) compared to stavudine(median 14.2 months; IQR
7.3–19.6) after start of treatment.
Changing the nucleoside reverse transcriptase
inhibitor used in first-line antiretroviral therapy
could explain the temporal trends in single-drug
substitutions
Adjusted competing risks regression models evaluating
the association between choice of NRTI used in first-line
ART and SDS helped us to confirm that the decrease in
rates of SDS was associated with the phasing out of
stavudine for tenofovir or zidovudine in first-line ART.
Adjusted models showed that patients initiating tenofovir
in Southern and East Africa were 20–95% less likely to
undergo a substitution than patients initiating stavudine
(Table 2). Posterior Bayesian estimates using an informa-
tive prior showed close to an 80% reduction in the risk of
SDS (posterior risk ratio 0.21, 95% CrI 0.20–0.22) when
comparing tenofovir to stavudine (Table 3). With the
exception of Zambia, where we saw an increase in the
hazards of SDS when comparing zidovudine to stavudine
(hazard ratio 2.59, 95%CI 2.3–3.0) and Kenya, where we
saw no association (HR 1.13, 95% CI 0.99–1.28) (Table
2), patients on zidovudine compared to stavudine in
Uganda, Cote d’Ivoire, and Nigeria had a 75–85%
decrease in the hazards of SDS when compared to
stavudine. Posterior Bayesian estimates using an infor-
mative prior showed close to a 70% reduction in the risk
of SDS (posterior risk ratio 0.31, 95% CrI 0.30–0.33)
(Table 3).
Our results also suggest that females compared to males
have a 50% increase in the risk of SDS (posterior risk ratio
1.48, 95% CrI 1.43–1.52) (Tables 2 and 3). Since we
believed changes in the trends of substitutions for sex
could vary by NRTI used in first-line ART, we calculated
the risk due to interdependence [R(I)]. With the
exception of Zambia and Kenya, where the R(I) was
essentially 0, the other four countries showed a positive
interdependence (Uganda 2%, Cote d’Ivoire 4%, South
Africa 5%, and Nigeria 6%). In other words, in Nigeria,
for example, 6% of SDS in women on stavudine is related
to the dual action of female sex and stavudine. The risk of
SDS in the doubly exposed (females exposed to stavudine)
was 41.9% versus the risk of 6.0% in the doubly
unexposed (males unexposed to stavudine). We did not
see any signs of interaction when assessing all other
biological relationships using the R(I).
We saw inconsistent results when comparing nevirapine
to efavirenz. In Zambia, Kenya, Uganda, and Nigeria, Copyright © 2016 Wolters Kluwepatients on nevirapine had a 10–70% increase in the risk
of SDS compared to those on efavirenz, whereas patients
in South Africa and Cote D’Ivoire had a decrease in SDS
of 20 and 40%, respectively. We also saw a decrease in the
risk of SDS by 10–40% in all countries amongst patients
with CD4þ cell count below 100 cells/ml compared to at
least 100 cells/ml.
Bias analysis
Bias analyses simulating a confounder that would
overestimate the effect of tenofovir or zidovudine versus
stavudine showed that in order for adjustment for an
unmeasured confounder to bring our results close to null,
the confounder would have to be present in 5% in those
exposed to tenofovir or zidovudine, extremely common
among patients exposed to stavudine (40%), and be a very
strong predictor of SDS (risk ratio>11.3), highly unlikely
(Supplementary Table 2, http://links.lww.com/QAD/
A998).Discussion
In the largest study to date, across multiple countries in
the African continent, we show steady decrease in SDS
corresponding to the phasing out of stavudine, in
accordance with the WHO guidelines, from an overall
rate of 11% prior to 2010, when 55% of patients were
initiating stavudine, to 5% after 2010, when only 7% of
patients initiated treatment with this drug. Using Bayesian
methods [32], although there was high heterogeneity
between studies for the majority of estimates, we were
able to estimate an 80% decrease in the risk of SDS when
comparing tenofovir to stavudine, and 70% decrease
when comparing stavudine to zidovudine, further
highlighting the better safety profile associated with
tenofovir and zidovudine compared to stavudine. Our
results also showed a decrease in the rates of SDS from
2005 to 2012 for patients on tenofovir, providing
evidence to support the notion that patients in earlier
years were being initiated on tenofovir due to contra-
indications to stavudine or zidovudine, and were there-
fore at a higher risk of toxicity/side effects.
Time to substitution varied depending on the NRTI used
in first-line ART, with zidovudine and tenofovir
occurring early after treatment initiation and at a higher
rate later on in follow-up amongst patients on stavudine.
This is consistent with previous studies conducted in sub-
Saharan Africa [12–20]; however, it is important to note
that time to substitution is partly a function of the
frequency of monitoring, which differs for each NRTI.
Laboratory monitoring for tenofovir and zidovudine is
often conducted early on after treatment initiation,
whereas for stavudine, monitoring begins more often
when the patient begins to develop clinical symptoms of
toxicity diagnosed at a medical visit [2,3]. Additionally,
although national guidelines for substitution of the NRTIr Health, Inc. All rights reserved.
 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
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156 AIDS 2017, Vol 31 No 1and NNRTI within first-line ART were the same, the
difference in estimates when comparing zidovudine to
stavudine, and also nevirapine to efavirenz could be due
to variation in monitoring practices or the availability of
NRTIs for substitution in each country.
Females, compared to males, had a 50% increase in the
risk of SDS in our study, consistent with previous research
[12,14–19]. By assessing effect measure modification on
the additive scale, we also showed that depending on
country, 2–6% of SDS in women on stavudine were
related to the dual action of female sex and stavudine.
Although we could not confirm the reason for
substitution in our study, previous research has reported
women on stavudine are at a higher risk of toxicity/side
effects than men [29,38,39], and that differences in risk of
toxicity observed between sexes could be related to
differences in susceptibility or to a higher level of
adherence to therapy achieved by women [29]. In
addition to the size of our study population, we were the
first to evaluate trends in SDS over almost a decade of
treatment in public sector since the roll out of ART in
2004 in six countries in sub-Saharan Africa. However,
our findings should be considered in light of the study
limitations. First, this study represents patients from urban
areas. Although some clinics are run out of tertiary
hospitals, the majority operate at the primary care level,
are led by nurses or clinical officers rather than physicians,
and are part of the public healthcare system of the country,
and may, therefore, not be generalizable to other clinics.
Second, there was variability in the estimates of the
association between NRTI used in first-line ART and
SDS by country. When comparing tenofovir to
stavudine, we saw a 20–95% decrease in the hazards of
SDS, and when comparing zidovudine to stavudine, we
saw a 85% reduction to a 200% increase in the hazards of
SDS. Although national guidelines for substitution of the
NRTI within first-line ART were the same in all six
countries, the difference could be due to variation in
monitoring practices at the level of the clinic or clinician
or the availability of alternative NRTIs used for
substitution. Third, due to the lack of documentation
of reasons for SDS for almost 95% of events amongst
patients with the event, we are likely underestimating the
frequency and type of side effects due to less-than-perfect
surveillance. There is a chance that SDS in our study were
driven by the policy change and not by side effects/
toxicity of stavudine. When we conducted this study in
our pediatric population, we did see a substantial spike in
SDS around the time of the guideline change as clinicians
were substituting stavudine, regardless of the fact that the
patient was tolerating stavudine well, with zidovudine or
tenofovir. If substitutions were being driven by the
guidelines in adults, we believe we would see a similar
increase, which is not present in these data. Fourth,
patients with lower CD4þ cell count (<100 cells/ml) had
upwards of 40% decrease in the risk of SDS over the
follow-up period in some countries. As we do see higher Copyright © 2016 Wolters Kluwer Hrates of attrition in patients with a lower CD4þ cell count
(<100 cells/ml to 23.6% vs. 100 cells/ml to 14.2%), the
decreased risk amongst patients with poorer immune
status could be caused by survivor bias. Fifth, in order to
strengthen the argument for further reduction in the cost
in tenofovir and zidovudine for use in LMICs, we
recognize that it would be important to know the
proportion of individuals who are symptomatic with
toxicity related to stavudine-based therapy and did not
experience a SDS. Unfortunately, conditions are poorly
captured in the database, preventing us from accurately
assessing symptoms among patients who did not have a
SDS. However, Fig. 1 shows that the policy change
switching to tenofovir was the reason for the decline in
SDS in South Africa, as the country went from almost
100% of patients initiating stavudine prior to the 2010
guidelines changing to less than 10%, which we believe
allowed us to evaluate what a change in national policy to
included tenofovir in first-line ART might do in other
countries as theymake the change. Sixth, it is possible that
our populations differed with respect to some unmea-
sured confounders, as data on WHO staging were not
available for Kenya and Uganda. We may therefore have
residual confounding in our estimates from those
countries. However, our bias analysis suggests such an
unmeasured confounder would be extremely unlikely in
our cohort. Finally, multiple imputation helps make it
possible to handle missing data routinely and improve the
validity of research. However, deviations from the
assumptions needed [34] could have led to unpredictable
biases in our parameter estimates.
Conclusion
The decline in SDS in the first 24 months on treatment is
associated with phasing out of stavudine for zidovudine or
tenofovir in first-line ART in the countries included in
our study. When calculating the number needed to treat,
we found that to prevent one additional SDS event, six
patients would need to be treated over 24 months, which
would be considered beneficial, supporting further efforts
to decrease the cost of tenofovir and zidovudine for use
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